Adult acute leukemia

Area of Science:

• Hematology
• Oncology
• Clinical Pathology

Background:

• Untreated acute leukemia is fatal within months.
• Current treatments improve survival but often result in relapse or treatment complications.
• Effective management necessitates differentiating acute myeloid leukemia (AML) from acute lymphoblastic leukemia (ALL) and identifying prognostic factors.

Purpose of the Study:

• To outline essential components for effective acute leukemia treatment.
• To detail diagnostic methods including morphology, cytochemistry, and immunophenotypic/karyotypic analyses.
• To discuss treatment strategies, remission induction, postremission therapy, and the role of prognostic factors.

Main Methods:

• Diagnosis relies on bone marrow aspirates showing ≥30% blast cells.
• Distinguishing AML from ALL uses morphology, cytochemistry, and immunologic/karyotypic analyses.
• Prognostic factors such as age, karyotype, and disease origin (de novo vs. secondary) are crucial.

Main Results:

• Accurate classification of AML and ALL subtypes, like acute promyelocytic leukemia (APL), is critical for specific treatment.
• Complete remission (CR) is the primary goal of induction therapy.
• Relapse remains common, and intensified therapy may offer benefits but carries substantial risks.

Conclusions:

• Optimal acute leukemia treatment hinges on precise diagnosis, risk stratification, and tailored therapeutic selection.
• Patients with unfavorable prognostic factors may require novel or investigational approaches beyond conventional chemotherapy.
• Further research into intensified therapies and personalized treatment strategies is warranted to improve outcomes.